Innoviva (INVA) Net Equity Issued and Repurchased (2010 - 2026)
Innoviva's (INVA) quarterly Net Equity Issued and Repurchased came in at $259000.0 in Q1 2026, up 3.6% YoY from $250000.0 in Q1 2025, and down 84.9% on a QoQ basis from $1.7 million in Q3 2025.
Innoviva (INVA) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Net Equity Issued and Repurchased data on file, last reported at $259000.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 3.6% year-over-year to $259000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 97.57% YoY) and the FY2025 annual result came in at $2.6 million, up 74.15% from the prior year.
- Net Equity Issued and Repurchased fell to $259000.0 in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $1.7 million in Q3 2025 to a low of $81000.0 in Q2 2022.
- A 5-year average of $493250.0 and a median of $259500.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased sank 67.54% — and 2025, when it soared 709.55%.
- Tracing INVA's Net Equity Issued and Repurchased over 5 years: stood at $342000.0 in 2022, then slumped by 67.54% to $111000.0 in 2023, then jumped by 687.39% to $874000.0 in 2024, then surged by 96.22% to $1.7 million in 2025, then sank by 84.9% to $259000.0 in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $259000.0 (Q1 2026), $1.7 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Jun 30, 2026 | 1.76 Mn |
| Mar 31, 2026 | 259,000.00 |
| Mar 31, 2026 | 259,000.00 |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 250,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Sep 30, 2024 | 874,000.00 |
| Sep 30, 2024 | 874,000.00 |
| Jun 30, 2024 | 157,000.00 |
| Jun 30, 2024 | 157,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Jun 30, 2023 | 111,000.00 |
| Jun 30, 2023 | 111,000.00 |